OncoMatch/Clinical Trials/NCT05394259
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
Is NCT05394259 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Piflufolastat F18 for pancreatic cancer.
Treatment: Piflufolastat F18 — To learn if piflufolastat F18 can be used in imaging scans for patients with breast cancer, HCC, or pancreatic cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Breast Carcinoma
Hepatocellular Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Patients who have had chemotherapy...within 4 weeks prior to PYLARIFY (piflufolastat F18) injection.
Cannot have received: immunotherapy
Patients who have had...immunotherapy...within 4 weeks prior to PYLARIFY (piflufolastat F18) injection.
Cannot have received: radiotherapy
Patients who have had...radiotherapy within 4 weeks prior to PYLARIFY (piflufolastat F18) injection.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05394259 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, immunotherapy, radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages